Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Rebus Holdings, Inc. focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. The company was founded in 2003 and is based in Westlake Village, California.
Buy
Sell